Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818. Pikavation is a wholly-owned subsidiary of Synnovation. SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase I/II clinical trials for the treatment of… Read More